{"id":"W3109355046","doi":"10.1080/09546634.2020.1839008","title":"Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; LEO Pharma; Sanofi Genzyme; Incyte; Medac; XBiotech; Kiniksa Pharmaceuticals; Fresenius Medical Care North America; Dermira; UCB Pharma; Regeneron Pharmaceuticals; Les Laboratories Pierre Fabre; Biogen; Celgene; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Atopic dermatitis; Dermatology; Randomized controlled trial; Corticosteroid; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003097272,0.0007980779,0.002289535,0.000353759,0.0003392526,0.001245279,0.0005990963,0.001333183,0.003042723],"category_scores_gemma":[0.003179791,0.0003029878,0.002703943,0.0007325662,0.0004976647,0.0005773302,0.0002935122,0.001265534,0.0003059031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008169327,"about_ca_system_score_gemma":0.000942325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009996812,"about_ca_topic_score_gemma":0.003594957,"domain_scores_codex":[0.9989228,0.0005855578,0.0001422045,0.0001229746,0.0001249064,0.0001015514],"domain_scores_gemma":[0.9980058,0.0006410263,0.0007407419,0.0001157363,0.0001903853,0.0003063123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8971375,0.00486712,0.01194547,0.004495279,0.01461903,0.0001009537,0.000098952,0.0005477821,0.004452917,0.0001068435,0.003277082,0.05835107],"study_design_scores_gemma":[0.8651896,0.07477239,0.04451397,0.0003934207,0.01103972,0.0002159331,0.00007636224,0.0006098676,0.0007884674,0.000141194,0.002212813,0.00004621716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.95151,0.03751727,0.0004016373,0.001148528,0.0002880106,0.003145194,0.003137459,0.00006550222,0.002786541],"genre_scores_gemma":[0.9845327,0.008700712,0.0006256485,0.00108553,0.0002245176,0.001727066,0.002308306,0.000009758963,0.0007858474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003097272,"threshold_uncertainty_score":0.01638013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03295868150867071,"score_gpt":0.3156504988386487,"score_spread":0.282691817329978,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}